The first antiviral nasal spray in the United States. Nomovid™ Nasal Spray will be easy-to-use, low-cost and can be quickly made available over-the-counter for consumers.

The new drug program aims to decrease the amount of UTIs that would otherwise require antibiotic intervention.

Three studies report promising results in the use of cutting-edge genome editing and cellular therapies for hard-to-treat blood disorders and cancers.

Within 24 hours of the first dose of Silmitasertib the patient showed significant clinical improvement and the oxygen requirement was weaned to room air. The patient was discharged from the hospital five days after starting Silmitasertib.